|
127 Companies |
|
139 Products |
|
139 Products |
|
89 Mechanisms of Action |
|
9 Trials |
|
1220 News |
|
| «12...13141516171819202122232425» |
- MK-2206 / Merck (MSD)
Enrollment closed, Metastases: S1005: Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - May 27, 2013
P2, N=64, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: XAGastric: Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma (clinicaltrials.gov) - May 27, 2013
P2, N=37, Active, not recruiting, Sponsor: Duke University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Trial completion: Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis (clinicaltrials.gov) - May 27, 2013
P2, N=287, Completed, Sponsor: Evoke Pharma
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed: A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer (clinicaltrials.gov) - May 22, 2013
P2a, N=30, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial termination, HEOR: Needs Assessment Evaluating Quality of Life Issues for Gastroparesis Patients and Caregivers (clinicaltrials.gov) - May 16, 2013
P=N/A, N=68, Terminated, Sponsor: University of Florida
Recruiting --> Active, not recruiting Recruiting --> Terminated; PI left institution,replacement PI not able to do study.
- Enrollment change, HEOR: Needs Assessment Evaluating Quality of Life Issues for Gastroparesis Patients and Caregivers (clinicaltrials.gov) - May 16, 2013
P=N/A, N=68, Terminated, Sponsor: University of Florida
Recruiting --> Terminated; PI left institution,replacement PI not able to do study. N=200 --> 68
- carboplatin / Generic mfg., capecitabine / Generic mfg., epirubicin / Generic mfg.
Trial completion, Metastases: Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer (clinicaltrials.gov) - May 15, 2013
P1, N=46, Completed, Sponsor: University of Nebraska
N=200 --> 68 Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial termination: Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract (clinicaltrials.gov) - May 14, 2013
P2, N=7, Terminated, Sponsor: The University of Texas, Galveston
Active, not recruiting --> Completed Completed --> Terminated; Administratively Terminated
- ||||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Enrollment change: Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis (clinicaltrials.gov) - May 13, 2013
P3, N=55, Completed, Sponsor: PT Otsuka Indonesia
Completed --> Terminated; Administratively Terminated N=45 --> 55
- ||||||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial completion: Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis (clinicaltrials.gov) - May 13, 2013
P3, N=55, Completed, Sponsor: PT Otsuka Indonesia
N=45 --> 55 Recruiting --> Completed
- epinephrine / Generic mfg.
Enrollment change: Resolution Endoclips Vs Epinephrine Injection and Heater Probe (clinicaltrials.gov) - May 9, 2013
P3, N=103, Terminated, Sponsor: Chinese University of Hong Kong
Recruiting --> Completed N=948 --> 103
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial: A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer (clinicaltrials.gov) - May 9, 2013
P2, N=52, Completed, Sponsor: Seoul National University Hospital
- Farydak (panobinostat) / Secura Bio
Trial termination, Epigenetic controller, Metastases: Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008) (clinicaltrials.gov) - Apr 29, 2013
P2, N=28, Terminated, Sponsor: Technische Universit
N=948 --> 103 Recruiting --> Terminated; medical/ethical reasons
- Zaltrap (ziv-aflibercept IV) / Sanofi
New P1 trial, Metastases: MOMENTUM1: Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers (clinicaltrials.gov) - Apr 29, 2013
P1, N=42, Recruiting, Sponsor: Jules Bordet Institute
- ||| Herceptin (trastuzumab) / Roche
Enrollment open: EVIDENCE: A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer (clinicaltrials.gov) - Apr 28, 2013
P=N/A, N=3500, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Terminated; medical/ethical reasons Not yet recruiting --> Recruiting
- |||||||||| Liporaxel (paclitaxel oral) / Dae Hwa, HaiHe Biopharma
New P3 trial, Metastases: DREAM: Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol (clinicaltrials.gov) - Apr 23, 2013
P3, N=238, Recruiting, Sponsor: Daehwa Pharmaceutical Co., Ltd.
- |||||| Liporaxel (paclitaxel oral) / Dae Hwa, HaiHe Biopharma
Enrollment open, Metastases: DREAM: Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol (clinicaltrials.gov) - Apr 21, 2013
P3, N=238, Recruiting, Sponsor: Daehwa Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion: ComVi and D-type Stent in Malignant GOO (clinicaltrials.gov) - Apr 21, 2013
P=N/A, N=89, Completed, Sponsor: Ajou University School of Medicine
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment open, Metastases: SOPP: S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer (clinicaltrials.gov) - Apr 18, 2013
P3, N=338, Recruiting, Sponsor: Min-Hee Ryu
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- ||| rilotumumab (AMG 102) / Amgen
Trial initiation date, Metastases: AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer (clinicaltrials.gov) - Apr 11, 2013
P1/2, N=130, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting Initiation date: Aug 2008 --> Feb 2009
- | cisplatin / Generic mfg., paclitaxel / Generic mfg., epirubicin / Generic mfg.
New P2 trial: Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer (clinicaltrials.gov) - Apr 10, 2013
P2, N=61, Recruiting, Sponsor: Centre Hospitalier Universitaire de Besancon
- New P2/3 trial: Residual Gastric Volume After the Ingestion of a Beverage Containing Carbohydrates Plus Whey Protein (clinicaltrials.gov) - Apr 8, 2013
P2/3, N=30, Completed, Sponsor: Federal University of Mato Grosso do Sul
- sunitinib / Generic mfg.
Trial completion, Metastases: Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer (clinicaltrials.gov) - Apr 7, 2013
P2, N=116, Completed, Sponsor: Samsung Medical Center
Initiation date: Aug 2008 --> Feb 2009 Active, not recruiting --> Completed
- |||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P3 trial, Metastases: S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients (clinicaltrials.gov) - Apr 2, 2013
P3, N=446, Not yet recruiting, Sponsor: Sun Yat-sen University
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Metastases: Postoperative Chemoradiotherapy With S-1 in Gastric Cancer (clinicaltrials.gov) - Apr 2, 2013
P2, N=46, Completed, Sponsor: Chonnam National University Hospital
- Ixempra (ixabepilone) - Otsuka, R / Pharm
Trial completion, Metastases: BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy (clinicaltrials.gov) - Apr 2, 2013
P2, N=0, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
New P2 trial: Botulinum Toxin for Stomach Cancer Treatment (clinicaltrials.gov) - Mar 31, 2013
P2, N=10, Recruiting, Sponsor: St. Olavs Hospital
- |||| tasquinimod (ABR-215050) / Active Biotech, Ipsen
Enrollment open: A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers (clinicaltrials.gov) - Mar 30, 2013
P2, N=196, Recruiting, Sponsor: Ipsen
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial termination, Surgery, Metastases: Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Mar 28, 2013
P2, N=25, Terminated, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Not yet recruiting --> Recruiting Completed --> Terminated
- |||| Trial completion: Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer (clinicaltrials.gov) - Mar 28, 2013
P4, N=1184, Completed, Sponsor: Eisai Co., Ltd.
Completed --> Terminated Recruiting --> Completed
- Zokinvy (lonafarnib) / Eiger
Enrollment change: A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) (clinicaltrials.gov) - Mar 26, 2013
P1/2, N=5, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed N=82 --> 5
- | Enrollment open: Acupuncture for Patients With Function Dyspepsia (clinicaltrials.gov) - Mar 25, 2013
P3, N=200, Recruiting, Sponsor: Chengdu University of Traditional Chinese Medicine
N=82 --> 5 Not yet recruiting --> Recruiting
- |||| Trial completion: Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis (clinicaltrials.gov) - Mar 25, 2013
P2, N=201, Completed, Sponsor: Tranzyme, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- AST-301 / University of Washington, Aston Sci., EpiThany
Trial completion, Metastases: Biological Therapy in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Mar 25, 2013
P=N/A, N=3, Completed, Sponsor: Duke University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial termination, Surgery, Tumor cell: EIPL;UMM-EIPL: Elimination of Peritoneal Tumor Cells With Extensive Peritoneal Lavage During Surgery in Patients With Gastric Cancer (clinicaltrials.gov) - Mar 20, 2013
P=N/A, N=64, Terminated, Sponsor: University Hospital Mannheim
Active, not recruiting --> Completed Recruiting --> Terminated; Prematurely halted after interim data analysis
- || oxaliplatin / Generic mfg., capecitabine / Generic mfg.
New P3 trial, Metastases: Neo-CRAG: Neoadjuvant Chemoradiotherapy vs. Chemotherapy With Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer (clinicaltrials.gov) - Mar 19, 2013
P3, N=620, Recruiting, Sponsor: Sun Yat-sen University
- |||||| TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
Enrollment open, Combination therapy, Monotherapy, Metastases: Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer (clinicaltrials.gov) - Mar 18, 2013
P3, N=400, Recruiting, Sponsor: Kuhnil Pharmaceutical Co., Ltd.
Recruiting --> Terminated; Prematurely halted after interim data analysis Not yet recruiting --> Recruiting
- imatinib / Generic mfg., cisplatin / Generic mfg., capecitabine / Generic mfg.
Enrollment change, Metastases: Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer (clinicaltrials.gov) - Mar 17, 2013
P1, N=38, Completed, Sponsor: Technische Universit
Not yet recruiting --> Recruiting N=28 --> 38
- sirolimus / Generic mfg.
New P1 trial: Sirolimus for Eosinophil-Associated Gastrointestinal Disorders (clinicaltrials.gov) - Mar 17, 2013
P1, N=75, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- |||||||||| TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
New P3 trial, Combination therapy, Monotherapy, Metastases: Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer (clinicaltrials.gov) - Mar 14, 2013
P3, N=400, Recruiting, Sponsor: Kuhnil Pharmaceutical Co., Ltd.
- |||| Trial completion: Study to Assess the Efficacy and Safety of SK-MS10 in Subjects With Acute and Chronic Gastritis (clinicaltrials.gov) - Mar 13, 2013
P2, N=102, Completed, Sponsor: SK Chemicals Co.,Ltd.
N=28 --> 38 Recruiting --> Completed
- |||||| esomeprazole / Generic mfg.
Enrollment open: High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer (clinicaltrials.gov) - Mar 11, 2013
P3, N=600, Recruiting, Sponsor: AstraZeneca
Recruiting --> Completed Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly
Enrollment change, Metastases: Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin (clinicaltrials.gov) - Mar 7, 2013
P2, N=16, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting N=25 --> 16
- golvatinib (E7050) / Eisai
Trial termination, Combination therapy, Metastases: E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer (clinicaltrials.gov) - Mar 5, 2013
P1/2, N=7, Terminated, Sponsor: Eisai Inc.
N=25 --> 16 Active, not recruiting --> Terminated; Sites not recruiting
- | relamorelin (RM-131) / AbbVie
Trial completion: Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis (clinicaltrials.gov) - Mar 5, 2013
P1, N=20, Completed, Sponsor: Rhythm Pharmaceuticals, Inc.
Active, not recruiting --> Terminated; Sites not recruiting Recruiting --> Completed
- Enrollment change: Effect of Gastrectomy and Anastomosis on Diabetes and Hypertension in Early Gastric Cancer Patients (clinicaltrials.gov) - Mar 3, 2013
P=N/A, N=150, Recruiting, Sponsor: National Cancer Center, Korea
Recruiting --> Completed N=120 --> 150
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment change, Surgery: Adjuvant Treatment of Gastric Cancer With Chemotherapy and Chemoradiotherapy (TRACE) (clinicaltrials.gov) - Mar 3, 2013
P2, N=63, Completed, Sponsor: University Hospital, Rouen
N=120 --> 150 N=42 --> 63
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion, Surgery: Adjuvant Treatment of Gastric Cancer With Chemotherapy and Chemoradiotherapy (TRACE) (clinicaltrials.gov) - Mar 3, 2013
P2, N=63, Completed, Sponsor: University Hospital, Rouen
N=42 --> 63 Active, not recruiting --> Completed
- Enrollment change: Natural History of Non-steroidal Anti-inflammatory Drug and Non-Helicobacter Pylori in Bleeding Peptic Ulcers (clinicaltrials.gov) - Feb 27, 2013
P=N/A, N=391, Completed, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Completed N=1300 --> 391
- Trial completion: Natural History of Non-steroidal Anti-inflammatory Drug and Non-Helicobacter Pylori in Bleeding Peptic Ulcers (clinicaltrials.gov) - Feb 27, 2013
P=N/A, N=391, Completed, Sponsor: Chinese University of Hong Kong
N=1300 --> 391 Active, not recruiting --> Completed